Modifier 25 Under Fire Again: 2026 BCBS and Cigna Policy Changes Denying Same‑Day E/M (99213) with Cryotherapy (17000)
The latest round of so-called “payment integrity” edits
By April 2026, both Blue Cross Blue Shield and Cigna had quietly tightened their claim‑editing rules for office visits billed with minor procedures. The big target again: modifier 25. They’re flagging every 99213 sent with 17000 (destruction of premalignant lesion, up to 14 lesions) and routinely denying the E/M as “not separately payable.”
This isn’t new, only sharper. BCBS rolled the edit into its “Professional Claim Editing and Reimbursement Policy” effective March 15 2026, run through the Optum ClaimsXten engine. Cigna switched on a matching edit February 10 2026 in its “Evaluation &. Management with Minor Procedures” update, referencing “duplicate payment for pre‑ and post‑service work.” Even when the visit documentation shows a genuinely significant, separately identifiable service, denials are auto‑generated with little to no human eyes on them.
And the hit adds up fast. Practices that skip appeals or rebills lose roughly $38‑$72 per visit, depending on region and contract. In a busy dermatology or family medicine office, that’s real revenue, literally thousands gone before anyone notices.
When 99213 + 17000 goes bad
Picture this: a PCP sees a patient for a six‑month skin check and cerumen removal. Multiple actinic keratoses are examined, sun exposure counseling happens, and cryotherapy is done on one lesion. The visit meets 99213 for MDM, and the cryo qualifies as 17000. So the claim goes out as:
99213‑25, 17000 (ICD‑10 L57.0 for actinic keratosis, H61.23 for impacted cerumen, etc.)
In Q4 2025, that paid fine. Post‑March 2026? BCBS knocks out 99213 as “inclusive,” citing policy 012‑R “E/M Services with Minor Surgical Procedures.” They argue the lesion evaluation wasn’t significant or separately identifiable. Cigna uses CARC 97, remark M80, claiming “service not separately reimbursable.”
Even when the note shows multiple unrelated concerns, both payers require reconsideration within 90 days and demand a distinct diagnosis, unrelated to the procedure. Add a second diagnosis, the ear complaint, and many still reject it, saying the note doesn’t prove a “distinct” E/M. This kind of automation ignores CMS’s longstanding stance that E/M and minor procedures can coexist if properly documented. Commercial payers lean on CMS language but bend it to justify denial engines.
CMS’s stance, and what payers do with it
CMS hasn’t revised the rule. Modifier 25 still stands. The 2026 MPFS Final Rule definition remains unchanged: a significant, separately identifiable E/M service by the same provider on the same day as a minor procedure. The only thing shifting is how private payers reinterpret “payment integrity” to trigger prepayment reviews disguised as edits.
The April 2026 Federal Register interoperability proposal focused on prior auth and data exchange, not bundling. But commercial payers cite CMS’s general push for “program integrity” to defend their automation. They’re using post‑payment edits as a kind of stealth prior auth. Technically allowed. Operationally invasive. Misleading, absolutely.
RACmonitor’s May 2026 analysis of E/M coding changes for 2027 hit the nail on the head, payers use CMS’s documentation tightening as cover for stricter edits right now. Every 25 denial gets wrapped in “duplicate payment prevention” language, no matter how clean the note.
What happens to your revenue, and how to fight back
A paid 99213 runs about $92 Medicare or $110‑$125 commercial. 17000 brings $50‑$60. Lose the 99213, and you’re down around forty percent of visit value. Twenty such denials a week? Roughly $2,000 monthly slipping out the door. Because denials hit at the line‑item level, they hide in your remits unless someone digs deeper.
The answer isn’t flooding payers with resubmits. It’s better documentation and smarter claim scrubbing before anything leaves your EHR. Separate the medically necessary problem‑focused portion from the procedure note. Flag distinct diagnoses where they exist. Instead of burying “AK evaluation and cryo” in one blurb, write them up as clearly different events. Some practices even drop short flags like “Evaluation above and beyond procedure” to highlight the difference for audit review.
After that, analyze denial patterns. BCBS triggers on certain 99xxx + minor procedure combos, so configure your practice system to hold those for manual check‑off before submission. If a 25 is attached, make staff verify the note actually supports it. Waiting for denials is costlier than prevention; internal appeal costs easily run $15‑$20 per claim, and Cigna’s win rate on modifier 25 appeals hovered under 25 percent as of Q1 2026 per clearinghouse tracking in peer RCM networks.
One more thing, don’t take CARC 97 or M80 codes as the final word. If policy language conflicts with CPT rules, escalate as a provider dispute, not a standard appeal. Network contracts bind payers to CPT unless formally amended. BCBS and Cigna can’t assume global bundling without publishing it. If they skipped that disclosure, you’ve got a dispute case.
Everyone in RCM is talking about AI claim reviews and “interoperable” denial edits this year. CMS’s April 2026 rule accelerated that tech wave. But the more efficient the system, the faster denials fly. The sustainable fix isn’t chasing every one, it’s tightening upstream. Monday morning, run a report of your top five CPT 17000 pairings from Q1 2026. Review every 99213 with 25. If a peer coder wouldn’t agree it’s distinct within thirty seconds, it’s not good enough. Look, this isn’t about beating the robots. It’s about staying one clean chart ahead of them.